Journal article
Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.
Abstract
5048
Background: Enfortumab vedotin (EV) is an antibody drug conjugate recently approved to treat mUC following prior platinum and PD1/L1 inhibitors. The outcomes and patterns of therapy of pts following discontinuation of EV has yet to be studied. We investigated outcomes of pts who completed EV treatment for mUC at multiple institutions in order to identify benchmarks for evaluation of new agents following EV. Methods: …
Authors
Curran C; Pond GR; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Zhang J
Journal
Journal of Clinical Oncology, Vol. 38, No. 15_suppl, pp. 5048–5048
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2020
DOI
10.1200/jco.2020.38.15_suppl.5048
ISSN
0732-183X